SC
BMY icon

Swan Capital’s Bristol-Myers Squibb BMY Stock Holding History

Swan Capital’s Portfolio BMY Stock Details BMY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$8.53K Sell
148
-20
-12% -$1.15K ﹤0.01% 216
2026
Q1 		$10.2K Sell
168
-10
-6% -$583 ﹤0.01% 201
2025
Q4 		$9.6K Sell
178
-236
-57% -$11.4K ﹤0.01% 176
2025
Q3 		$18.7K Hold
414
– – 0.01% 123
2025
Q2 		$19.2K Hold
414
– – 0.01% 114
2025
Q1 		$25.3K Hold
414
– – 0.01% 87
2024
Q4 		$23.4K Sell
414
-256
-38% -$14.3K 0.01% 92
2024
Q3 		$34.7K Hold
670
– – 0.02% 83
2024
Q2 		$27.8K Buy
+670
New +$30K 0.02% 90

Other funds holding BMY

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Swan Capital's BMY Position: Q2 2026 in Review

Swan Capital reduced its Bristol-Myers Squibb (BMY) stake by 12% in Q2 2026, selling an estimated $1.15K and leaving 148 shares worth $8.53K. The position accounts for ﹤0.01% of the portfolio, ranked #216.

Swan Capital first reported a position in BMY in Q2 2024 and has held it in 9 quarters since. The position peaked at $34.7K in Q3 2024. 2,517 funds tracked by Wall St. Rank hold BMY as of Q2 2026.

  • Swan Capital held 148 shares of Bristol-Myers Squibb worth $8.53K as of Q2 2026.
  • Swan Capital sold 20 Bristol-Myers Squibb shares in Q2 2026, an estimated $1.15K.
  • Bristol-Myers Squibb made up ﹤0.01% of Swan Capital's portfolio in Q2 2026, its #216 holding.
  • Swan Capital first reported a position in Bristol-Myers Squibb in Q2 2024 and has held it in 9 quarters since.
  • Swan Capital's Bristol-Myers Squibb position peaked at $34.7K in Q3 2024.
  • 2,517 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q2 2026.

Based on Swan Capital's 13F filing for Q2 2026, filed 13 Aug 2026.